Trial Profile
Phase I Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL Amyloidosis or Light Chain Deposition Disease
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 11 May 2023
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Dexamethasone (Primary) ; Pomalidomide (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Adverse reactions
- 05 May 2023 Status changed from active, no longer recruiting to discontinued.
- 20 Jan 2023 Planned End Date changed from 1 Jan 2023 to 1 Jan 2024.
- 20 Jan 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Jan 2024.